A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects With Advanced Malignancies
Latest Information Update: 11 Dec 2023
At a glance
- Drugs Roducitabine (Primary)
- Indications Bladder cancer; Pancreatic cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Processa Pharmaceuticals; Rexahn Pharmaceuticals
- 03 Jan 2020 Status changed from active, no longer recruiting to completed.
- 10 Sep 2019 Planned End Date changed from 1 Mar 2019 to 1 Nov 2019.
- 10 Sep 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Oct 2019.